PROFESSIONAL EXPERIENCE

*.Otsuka VP Research and Emerging Sciences and head of Early-Stage Life science Investments Jan 2020-Present

My most recent position was created for me as VP for Research and Emerging Sciences Jan 2nd, 2020 to date-at Otsuka I helped incorporate and managed the early-stage investment fund and ran Search and Evaluation.

I championed 133 new programs for Otsuka-the first to pass was my deal with Rugen,

https://www.otsuka-us.com/discover/msrd-enters-collaboration-agreement-with-rugen, 5 more on the way

2. Wyeth Pharmacuticals 2003-2008 – Head of Traslational Medicine

6. CEO Bioasis Technologies Inc., Guilford, CT: A Canadian publically traded biotechnology firm dedicated to providing therapeutic solutions to patients suffering from neurological diseases and disorders.Responsible for providing cross-functional, leadership across business development, external/internal R&D, translational medicine and academic sciences across multiple therapeutic areas. I ran the operation with a small dedicated team. Set up the USA company, located offices, built the management team and Restructured the Board of Directors and established the SAB (John Krystal (Chair), Jeff Cummings, Neurology, Mario Saltarli, Sue OConnor, Jack Hoppin

Bristol Myers-Squibb (BMS), Wallingford, CT

Global Lead, CNS, Virology Business Development April 2012 to May 2014

Accountable for leading search, evaluation and due diligence in the U.S. and Europe for all of the company’s in-licensing and M&A interests for CNS, oncology, genetic disease and immune-virology.

Reorganized the process for identifying top-tier opportunities, implemented an outreach program to the US venture capital community, and achieved the highest business development search and evaluation statistics two years in a row. Led startup-phase 4 opportunities

Identified and ran M&A and licensing diligences on CNS, Oncology, Immunology, Virology and Genetic Disease, and served as the Chair of the Neuroscience License Steering Committees to align business strategy

E.g. Cytokinetics, Acadia, iPierian, Neurex, Allergan,Invivo and many more. I save the company millions of dollars by applying PTRS principles of Target Engagement, PD markers and patient selection criteria

Abbott Laboratories, Lake Bluff, IL

Head, Translational Imaging and Biochemical Biomarkers March 2009 to April 2012

Led the company’s identification and implementation of biomarkers to support late discovery and early development programs for all therapy areas. Demonstrated improved path into PoC and Abbott changed stage gate requirements for entry into Phase 1. Took Company from 0 biomarkers for internal programs to 18 in 12 R&D in translational activities, enabling alignment of strategies across therapeutic areas.

In the top 10% performance ranking of all Abbott employees 2009 and 2010

Raised the internal and external profile of Abbott Imaging

Chair Neuroscience, OA and Pain Biomarker Working Groups

Managed a team of 18 Ph.D., M.D., Technicians to develop translational in-house and external capabilities

Core team member for all strategy and long-range planning meetings across several sites (e.g., San Francisco, Boston, Germany)

Identified, established and maintained six new external collaborations and consortia to support biomarker studies (e.g., Asia, U.S., Europe)

Determined the full translational utility of a D3/D2 PET tracer to determine the in vivo selectivity of D3 antagonists. This research led to one clinical lead being terminated and the backup expedited into the clinic

Combined imaging and CSF markers into single NHP studies, and determined the full translational utility of a D3/D2 PET tracer to determine the in vivo selectivity of D3 antagonists

Published 18 novel CNS publications on CNS drug activity using imaging, microdialysis and other techniques

Edited the special issue on Translational Medicine of Biochemical Pharmacology

AFFILIATIONS

Society for Neuroscience, Society of Biological Psychiatry, Association of Pharmacology and Experimental Therapeutics, International Behavioral Neuroscience Society, International Society to Advance Alzheimer Research and Treatment, Parkinson’s UK Scientific Advisory Board, Scientific Advisor for BioAdvance

YALE UNIVERSITY

Associate Professor, Translational Neuroscience (Adjunct)

Give lectures on multi-disciplinary translational approaches to drug discovery and development

Develop experimental translational studies in NHP with aim of validation in humans. Current focus is on translating neurochemical changes using in vivo imaging

Foster strategic alliances between Yale and the pharmaceutical / biotech industry

SELECTED DEALS / ALLIANCES / RESEARCH COLLABORATIONS

In 2nd Q2020 I brought in 133 opportunities for Otsuka and executed the Rugen Collaboration Agreement is the first to pass the line several more to be announced.

https://www.otsuka-us.com/discover/msrd-enters-collaboration-agreement-with-rugen

IPierian Inc.: M&A. $150M upfront, $550M in milestones I identified the opportunity, evaluated, and presented business case to BMS, and was involved in technical negotiations.

Celgene: GABA-A antibody - Collaboration (USD$500k upfront, USD$2.5M in manufacturing and PET imaging). I led the Initiation, negotiation and execution.

Prothena: Licensing deal (USD$1M up front, up-to USD$33M in potential milestones), Initiation, negotiation, and execution.

Xoma: Royalty Purchase Agreement for USD$300K upfront, additional USD$225K for IND-enabling initiation for first company; negotiated rolling increased scale for future business development at 50% premium to first deal.

Undisclosed: Initiation, negotiation of large U.S. pharma deal for four targets currently under negotiations.

MJF foundation: for 500K grant, in the final two for selection to support Gaucher’s Disease program

Olipass. Worldwide collaboration for PNA on undisclosed targets (BMS, identified opportunity, conducted wet diligence via CRO and internal labs)

Santaris: Identified the opportunity with Discovery lead- gene modulation via ASO. $11 million upfront (BMS)

Universities of Edinburgh & Glasgow: “Imaging conditioned fear circuitry using awake rodent fMRI”. Published in PLoS One. 2013;8(1): e54197

University of Edinburgh: “Midbrain activation during Pavlovian conditioning and delusional symptoms in schizophrenia.” Published in Arch Gen Psychiatry. 2010 Dec; 67(12): 1246-54

MIT & Burke Rehabilitation Center: “Utility of Robot Arm as a pharmacodynamic biomarker for stroke recovery.” This study evaluated whether the robot arm in combination with an experimental therapeutic could synergize improve functional recovery and patient rehabilitation

Canadian Stroke Network: Established a Ph.D. program between CSN and Wyeth that supported 11 Ph.D. students. The program focused on ways of examining patient salvageable tissue area and new more predictive animal models of stroke treatment

The University of Aberdeen: Generation and characterization of Disc1 (TR) transgenic mice expressing 2 copies of truncated Disc1 encoding the first 8 exons using a bacterial artificial chromosome. Published in J Neurosci. 2008 Oct 22; 28(43): 10893-904

Asuragen: mRNA profiling in human CSF AMC, MCI and AD patients

Banyan Biomarkers: Effect of ABT-099 on NHP CSF and other novel biomarkers (e.g., TBI)

Invicro: Software and analytics for fMRI bone image analysis and brain atlas

Yale University: Three-year umbrella agreement for all targets

Abbott/Yale: Collaboration focused on NHP and human Phase 1 target engagement collaboration

Interivo Solutions: Aged dog CSF as a biomarker for MCI and ID

Purdue Pharma: SPECT radiotracer Tc99m to monitor antiangionenic therapy

Maccine (five-year research agreement)

oNHP CSF as PD marker of Calpain inhibition, D3, 5HT6, a7, H3 antagonists, etc.

oNovel model and analysis development of OA pain in NHP’s

oCognition drug profiling

Select Relevant Publications (full 80 MS list available on request)

#Day M*, Morris RG (2001). Memory consolidation and NMDA receptors: discrepancy between genetic and pharmacological approaches. Science. 3; 293(5531): 755

#Day M*, Langston R, Morris RGM (2003) Differential regional and glutamate receptor-dependent encoding, consolidation and retrieval of paired-associate learning. Nature. 424, 205-209

#Baker SJ, Chin, CL, Basso AM, Fox GB, Marek GJ & Day M (2012). Xanomeline Modulation of the BOLD Signal in Awake Rats: Development of phMRI as a Translatable Pharmacodynamic Biomarker for Central Activity and Dose Selection in Humans. J Pharmacol Exp Ther. 2012 Apr; 341(1): 263-73.

#Day M*, Balci F, Wan HI, Fox GB, Rutkowski JL, Feuerstein G (2008). Cognitive endpoints as disease biomarkers: optimizing the congruency of preclinical models to the clinic. Current Opinions in Investigational Drugs. 9(7): 696-706

#Day M*, Fox GB, Marek GJ (2011). Editorial: Translational Medicine special issue. Biochemical Pharmacology. 81, 1353-55

#Sakoğlu U, Upadhyay J, Chin CL, Chandran P, Baker SJ, Cole TB, Fox GB, Luo F, Day M*, (2011). Paradigm shift in translational neuroimaging of CNS disorders. Biochemical Pharmacology. 15; 81(12): 1374-87

#Chin CL, Upadhyay J, Marek GJ, Baker SJ, Zhang M, Mezler M, Fox GB, Day M* (2011). Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2/3-agonist modulation of ketamine-induced blood oxygenation level dependence signals. J Pharmacol Exp Ther. 336:709-15

#Luo F, Rustay NR, Cole T, Zhang Y, Seifert, Liano DA, Fox GB & Day M* Characterization of 7 and 19-month-old Tg2576 mice using multimodal in-vivo imaging: Limitations as a translatable model of Alzheimer's disease. Neurobiology of Aging

Harris AP., LennenRJ., Brydges N., Jansen MA., Pernet CR., Whalley H C., Marshall, I., Baker S., Baso, A., Day, M., Holmes, MC., Hall, J (Translational Psychiatry). The role of Brain Derived Neurotrophic Factor in learned emotional fear processing in rats: an awake fMRI study.

Brydges N, Sibley H, Jansen M, Merrifield G, Wood E, Lawrie S, Brash L, WynneSM, Day M, Fleetwood-Walker S, Steele JD, Marshall I, Hall J and Holmes MC (2013). Exploring Fear Processing in the Conscious Rodent Brain Using fMRI. PLoS One. 2013;8(1)

#Chandran P, Markosyan S, Upadhyay J, Fox GB, Luo F & Day M (2012). MRI and histological evidence for the blockade of Cuprizone-induced Demyelination in C57/Bl6 mice. Neuroscience. Jan 27; 202:446.

#Luo F, Rustay NR, Cole T, Zhang Y, Seifert, Liano DA, Fox GB & Day M* (in Press). Characterization of 7 and 19-month-old Tg2576 mice using multimodal in-vivo imaging: Limitations as a translatable model of Alzheimer's disease. Neurobiology of Aging

#Day M*, Bain E, Marek G, Saltarelli M, Fox GB (2010). D3 receptor target engagement in humans with ABT-925 using [11C] -PHNO PET. Int J Neuropsychopharmacol. 13(3): 291-2

#Day M*, Rutkowski JL, Feuerstein GZ (2009). Translational medicine--a paradigm shift in modern drug discovery and development: the role of biomarkers. Adv Exp Med Biol. 655:1-12

#Navarra R, Comery TA, Graf R, Rosenzweig-Lipson S, Day M* (2008). The 5-HT (2C) receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test. Behavioral Brain Research. 188(2): 412-5

#Chandran P, Markosyan S, Upadhyay J, Fox GB, Luo F & Day M (2012). MRI and histological evidence for the blockade of Cuprizone-induced Demyelination in C57/Bl6 mice. Neuroscience. Jan 27; 202:446.

REFERENCES

Richard Hargreaves, Ph.D., VP, Celgene: adryar@r.postjobfree.com

Prof. John H. Krystal, M.D., Yale University: adryar@r.postjobfree.com

Mario Saltarelli, M.D., Ph.D., CMO, Entrada: adryar@r.postjobfree.com

Doug Manion, M.D., CEO, Kleo: adryar@r.postjobfree.com

Charlie Albright, Ph.D., CSO, Editas adryar@r.postjobfree.com

John Renger, Ph.D., CSO, Cerevel adryar@r.postjobfree.com

Contact this candidate